Ms. Johnson, a 52-year-old woman, was diagnosed with stage III breast cancer and scheduled to undergo High Emetic Risk Chemotherapy (HEC) consisting of a combination of doxorubicin and cyclophosphamide. Given the high emetic potential of this chemotherapy regimen, the oncology team prescribed a triple therapy antiemetic regimen: 5-HT3 RA Steroid NK1 RA. Despite the triple therapy, Ms. Johnson experienced breakthrough nausea and vomiting during her first cycle of chemotherapy, significantly impacting her quality of life and ability to adhere to subsequent treatments. Which treatment option would you add to triple therapy (5-HT3 RA Steroid NK1 RA) for treatment of a High Emetic risk Chemotherapy (HEC)? A. Prochlorperazine PO B. Metoclopramide PO C. Fosaprepitant IV D. Olanzapine PO